Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Wendy DiCicco
AddedMar 31, 2024
UpdatedMay 31, 2026
Wendy DiCicco

Wendy DiCicco

Board Member, EyePoint

CrunchbaseLinkedIn

Wendy DiCicco's Career

EyePoint
EyePoint

Watertown, MA, US

Board Member· Board
ExpressCells
ExpressCells

Philadelphia, PA, US

Board Member· Board
Imvax
Imvax

Philadelphia, PA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Wendy DiCicco's Career

EyePoint
EyePoint
Public$653.8M1442008Watertown, MA, US
Board Member· Board

Leadership at EyePoint

John LandisJohn LandisBoard Member
Nancy LurkerNancy LurkerBoard Member
Göran AndoGöran AndoBoard Member
Jay DukerJay DukerCEO
Stuart M DutyStuart M DutyBoard Member

Similar to EyePoint

Hyperion DeFiHyperion DeFiNew York City, NY, USTherapeuticsest. 2014Hyperion DeFiNew York City, NY, US · est. 2014

Eyenovia, Inc.: A NASDAQ-listed biopharmaceutical firm innovating advanced ophthalmic therapeutics.

Public · $75.1M41
Eye-PharmaEye-PharmaLittle Rock, AR, USDrug Productsest. 2013Eye-PharmaLittle Rock, AR, US · est. 2013

Eye-Pharma, LLC: Innovating affordable ophthalmic drugs through reformulation in Little Rock, AR.

Seed · $145.5k7
Ocular TherapeutixOcular TherapeutixBedford, MA, USOphthalmic Therapiesest. 2006Ocular TherapeutixBedford, MA, US · est. 2006

Ocular Therapeutix, Inc.: Global biopharma innovator in hydrogel-based ophthalmic therapies.

Public · $386.5M274
Surface PharmaceuticalsSurface PharmaceuticalsDelaware, USPharmaceuticalsest. 2017Surface PharmaceuticalsDelaware, US · est. 2017

Delaware-based Surface Pharmaceuticals develops biotech solutions for dry eye diseases, serving California.

Series A · $46.8M8
ExpressCells
ExpressCells
Pre-Seed$1.8M82018Philadelphia, PA, US
Board Member· Board

Leadership at ExpressCells

Matthew HandelMatthew HandelCEO
Oscar Perez-LealOscar Perez-LealFounder

Similar to ExpressCells

CellFECellFEAlameda, CA, USCell Therapies, Gene Editingest. 2018CellFEAlameda, CA, US · est. 2018

CellFE: A cell engineering startup innovating efficient gene-editing delivery via microfluidic devices.

Series A · $26.8M35
CelldomCelldomDurham, NC, USSingle-Cell Analysisest. 2016CelldomDurham, NC, US · est. 2016

Celldom advances research and drug development with high-throughput, next-gen single-cell analysis technology.

Seed · $1.9M5
OpenCell TechnologiesOpenCell TechnologiesAtlanta, GA, USTransfection Toolsest. 2008OpenCell TechnologiesAtlanta, GA, US · est. 2008

OpenCell Technologies: Providing efficient, scalable transfection tools for Life Sciences research.

Angel · $225k5
CasTag BiosciencesCasTag BiosciencesDurham, NC, USBiotechnology, Cell Therapiesest. 2020CasTag BiosciencesDurham, NC, US · est. 2020

CasTag Biosciences: Innovating regenerative medicine and cell biology for faster scientific discovery.

Angel · $280.7k2
Imvax
Imvax
Series B$189.7M572015Philadelphia, PA, US
Board Member· Board

Leadership at Imvax

John FureyJohn FureyCEO
Peter B. CorrPeter B. CorrBoard Member
David AndrewsDavid AndrewsCo-Founder
D. Craig HooperD. Craig HooperCo-Founder

Similar to Imvax

Imvaq TherapeuticsImvaq TherapeuticsNew York City, NY, USCancer Treatmentest. 2018Imvaq TherapeuticsNew York City, NY, US · est. 2018

Imvaq: A biotech firm innovating immuno-oncologics for global cancer treatment.

Series B · $20M8
MimiVaxMimiVaxBuffalo, NY, USCancer Treatmentest. 2012MimiVaxBuffalo, NY, US · est. 2012

MimiVax: A clinical-stage biotech firm specializing in developing immunotherapeutic vaccines for cancer treatment.

Series B · $16.6M3
INmune BioINmune BioBoca Raton, FL, USCancer Treatmentsest. 2015INmune BioBoca Raton, FL, US · est. 2015

INmune Bio Inc., a US-based clinical-stage biotech firm, specializes in developing cancer treatments.

Public · $103.2M17
ImmunoGenesisImmunoGenesisHouston, TX, USCancer Therapiesest. 2019ImmunoGenesisHouston, TX, US · est. 2019

ImmunoGenesis: Developing science-based therapies to combat immune-resistant tumors.

Public · $28M38

Wendy DiCicco's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · KakaoSong Ji-Ho 'DeanSong Ji-Ho 'DeanBoard Member · Kakao

People Similar to Wendy DiCicco

Mark S CohenMark S CohenCo-Founder · DiscGenicsJack FuchsJack FuchsBoard Member · ConfraparLawrence FirestoneLawrence FirestoneBoard Member · 22nd Century GroupMichael PirainoMichael PirainoBoard Member · LabVoiceMardi C. DierMardi C. DierBoard Member · SynthekineBrian Di DonatoBrian Di DonatoBoard Member · Iecure